Biomarker ID | 1317 |
PMID | 24448834 |
Year | 2014 |
Biomarker | DAB2 [SNP: rs268091: GC/CC versus GG] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | Increased risk of Progression |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.36 (95% CI: 0.16–0.80) |
Effect on Pathways | Pathways include: Gap junction degradation, Gap junction trafficking and regulation, Membrane trafficking, TGF-beta signaling pathway, Endocytosis |
Experiment | PCa Specific Mortality Vs No Mortality During ADT |
Type of Biomarker | Prognostic |
Cohort | 321 patients with localized prostate cancer who underwent radical prostatectomy (RP) as initial treatment and 605 patients with advanced prostate cancer on androgen-deprivation therapy (ADT) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.012 |
Method Used | MALDI-TOF |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |